Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × atezolizumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 51 Carcinoma, Non-Small-Cell Lung 49 Lung Neoplasms 27 Neoplasms 23 Small Cell Lung Carcinoma 21 Breast Neoplasms 19 Colorectal Neoplasms 18 Melanoma 15 Neoplasm Metastasis 14 Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 13 Triple Negative Breast Neoplasms 12 Carcinoma, Renal Cell 10 Squamous Cell Carcinoma of Head and Neck 9 Stomach Neoplasms 8 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Glioblastoma 7 Endometrial Neoplasms 7 Uterine Cervical Neoplasms 6 Head and Neck Neoplasms 6 Pancreatic Neoplasms 5 Liver Neoplasms 5 Sarcoma 4 Rectal Neoplasms 4 Esophageal Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Neuroendocrine 4 Carcinoma, Merkel Cell 4 Brain Neoplasms 4

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡